Page Banner
Mayo Clinic Laboratories > Hematology > MayoComplete

MayoComplete

View now Hematology, oncology, and hereditary test selection guide
Podcast Decoding Cancer Care: The Role of Molecular Testing

Individualized answers for personalized care

Our menu of MayoComplete next-generation sequencing assays includes targeted testing for a growing list of hematologic cancers. Utilizing next-generation sequencing, our MayoComplete testing ensures each patient receives personalized answers to guide their care.

Test menu

Acute myeloid leukemia Acute myeloid leukemia
Acute myeloid leukemia

Our clinically validated testing for acute myeloid leukemia can provide critical diagnostic, prognostic, and therapeutic information for physicians.

B-cell lymphoma B-cell lymphoma
B-cell lymphoma

Offering two genetic panels to help profile B-cell lymphoma, our NGS testing evaluates dozens of genes with associations to B-cell lymphoma to help to characterize the cancer type, which can assist with differential diagnosis and targeted treatment selection.

Histiocytic neoplasms Histiocytic neoplasms
Histiocytic Neoplasms

Including genes commonly mutated in the biologic pathways associated with histiocytic neoplasms, our focused histiocytic panel provides insights on disease origins, differential diagnosis, and therapeutic decision-making.

Plasma cell myeloma Plasma cell myeloma
Plasma Cell Myeloma

Focused on genes implicated in multiple myeloma, our 26-gene panel can help characterize diagnosis, monitor for disease progression and transition, and clarify treatment targets. Our assay involves a pre-analytical step of cell sorting and only tests DNA from the plasma cell population, which increases testing sensitivity.

T-cell lymphoma T-cell lymphoma
T-cell Lymphoma

Our novel MayoComplete T-cell lymphoma panel examines 26 genes with known diagnostic, prognostic, or therapeutic association in a number of T-cell lymphoma subtypes, including angioimmunoblastic T-cell lymphoma and large granular lymphocytic leukemia. 

MayoComplete next-generation sequencing overview MayoComplete next-generation sequencing overview
MayoComplete next-generation sequencing overview

Designed using our extensive clinical experience and informed by the latest in cancer biomarker discovery and treatments, our suite of MayoComplete next-generation sequencing panels puts patients on the right path.

Precision testing for individual insights

MayoComplete disease-specific, next-generation sequencing hematology panels provide focused insights on genetic variations found in hematological cancers to optimize treatment outcomes. MayoComplete hematology testing includes both comprehensive and targeted assays.

Testing advantages

  • Developed, validated, analyzed, and reported by experts.
  • Guides decisions on optimal treatment options, including targeted immunotherapies.
  • High accuracy and sensitivity.
  • A full menu of complementary microarray, FISH, and IHC testing available, providing full-spectrum testing in one laboratory.

Clear answers, definitive reports

Because testing is complex and selecting the right assay can be challenging, our team of board-certified geneticists and genetic counselors is available to assist with questions related to testing options and results interpretation.

MayoComplete next-generation sequencing includes detailed reports that highlight diagnostic findings, therapeutic associations, availability of on- and off-label therapies, prognostic markers, and existence of applicable clinical trials that enable deeper understanding of the best treatment choices.

(BETA) Choose a language to view this content in:
About the translation.